Skip to main content
Premium Trial:

Request an Annual Quote

Simulations Plus, FDA to Collaborate on Drug Development Study

Premium

Simulations Plus said this week that it has signed a five-year research collaboration agreement with the US Food and Drug Administration to work on determining the value of mechanistic absorption modeling (MAM) in developing predictive and robust in vitro/in vivo correlations.

Specifically, the collaborators will explore how MAM can be used to make more accurate predictions of complex drug absorption characteristics. The ultimate goal of the project, the company said in a statement, is to "facilitate drug and generic product development by decreasing the regulatory burden through adequate modeling approaches."

As part of the agreement, Simulations Plus will provide training and licenses for its GastroPlus simulation software to the FDA's Office of Testing and Research. The solution will be used to "model in vivo data [that is] representative of challenging absorption characteristics, the company said.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.